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The safety and efficacy of treatment options for patients with haemophilia have significantly improved over the
last two decades, particularly with greater utilization of prophylactic approaches. Consequently, it is becoming
increasingly difficult to differentiate the treatment benefits of available choices based on standard endpoints such
as annualized bleeding rates and joint health scores. Patient-reported outcomes (PROs) have shown limited ability
to discriminate between treatment outcomes, in part because of their comprehensive nature; i.e. differences in
specific outcomes meaningful to individual patients are masked by a global scoring system based on a fixed set of
items, many of which may be unimportant for any given patient. There is a clear need for new outcome
measures. Initiatives to develop patient-centric outcomes that capture clinically meaningful change are ongoing.
One such approach, goal attainment scaling (GAS), allows patients, in collaboration with a trained clinician, to
select goals from a medical condition-specific menu of options and subsequently facilitates quantitative
assessment of goal realization. Thus, it is fully personalized and sensitive to small, often idiosyncratic, treatment
benefits, such as improvements in functional capacity. In this paper, we present the underlying rationale for GAS
and one other novel approach to PRO personalization, and discuss their potential to augment current outcome
measures by reliably detecting and quantifying treatment effects in individuals with haemophilia on prophylaxis.
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Introduction
Controlled clinical studies in persons with haemophi-
lia (PwH) have confirmed the superior efficacy of pro-
phylactic factor replacement regimens compared to
episodic treatment [1,2]. As a result, prophylaxis regi-
mens have been adopted as standard of care in
patients with severe disease, significantly reducing
bleeding rates and improving joint health in this popu-
lation [1]. PwH residing in industrialized countries
now aim to live a life with little to no bleeding. Thus,
the positive changes effected by prophylaxis regimens
have established an elevated state of health and have
fundamentally changed the goals of therapy. In addi-
tion, these goals are individualized, based on life cir-
cumstances and personal aspirations that differ
considerably among individuals over a lifespan.
Outcome measures currently used in haemophilia
clinical studies are variably applied in clinical practice,
having not been designed to identify or measure the
most important treatment goals for individuals. Cur-
rent treatment outcome measures, including the annu-
alized bleeding rate (ABR), joint health scores and
validated quality-of-life (QoL) instruments, were
designed to measure common or global endpoints that
are not personalized. Therefore, these instruments,
while relevant in clinical research, may be of limited
value in the current and future practice of clinical care
for haemophilia, where individual perspectives on
improved health outcomes vary widely. New tools are
needed that can detect the benefits of treatment that
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matter to individual patients and be readily integrated
with routine patient care. In addition, as ABR
approaches zero, the clinical meaningfulness of small
differences among prophylaxis regimens is unclear.
Thus, we also envision the use of such tools as adjunc-
tive measures in clinical research, particularly with
respect to comparative effectiveness studies.
Furthermore, patient perspectives on treatment goals
and success may differ from those of their physicians
and caregivers [3]. For example, with the advent of
prophylaxis, treatment adherence is an important con-
sideration in the management of haemophilia from the
health care provider’s perspective. From the patient’s
perspective, however, adherence to treatment recom-
mendations depends on whether, and to what extent,
such adherence serves as a means to realize personal
goals [4–6]. While clinicians intuitively recognize and
incorporate patients’ goals in treatment planning, the
field lacks a formal patient-reported outcome (PRO)
measure to document this aspect of treatment and
serve as a means to evaluate treatment effectiveness.
Therefore, a new outcome measure that can enhance
the ability to compare effectiveness among available
treatment options is needed. Indeed, using patient-cen-
tric approaches to define outcomes is becoming
increasingly common in the medical management of
chronic conditions, including diabetes [7], multiple
sclerosis [8] and allergic disease [9].
Individualized goal-setting represents a form of per-
sonalized medicine distinct from molecular-based
approaches to treatment selection for individual
patients, commonly known as precision medicine [10].
Although precision medicine offers personalization
from the perspective of genes and proteins, it cannot
take into account the patient’s goals or preferences
and the impact of treatment on daily living. Ideally,
such patient-centric metrics would encompass the
patient’s clinical course, lifestyle preferences and
personal aspirations, and provide an objective/semi-
quantitative output to gauge treatment success. This
would require that the tool be comprehensive in
scope, comprising an array of clinical/functional
parameters, while allowing each patient to select only
those endpoints that are personally meaningful. It is
also of critical importance that this should be achiev-
able in a time- and resource-efficient manner, particu-
larly when administered in a real-world setting.
In this article, we review the strengths and limita-
tions of outcome measures used currently in haemo-
philia clinical practice and research. Ongoing efforts
to develop novel outcome measures that address these
common limitations are then introduced.
Clinically assessed outcome measures
Key endpoints traditionally evaluated in PwH are
based on clinical manifestations of the disease, such as
bleeding events and joint dysfunction. The latter is
critical because the majority of bleeding events occur
in joints [11,12]. To further evaluate joint status,
anatomical evaluations using various imaging modali-
ties are commonly employed.
Annualized bleeding rate
The ABR is a measure of bleeding frequency and
treatment effectiveness in the clinic, and is often the
primary outcome in clinical studies involving PwH
[13,14]. With respect to the latter, it has been
especially valuable as a means of documenting the
superior efficacy of prophylaxis in comparison with
on-demand therapy [2,12]. However, because ABR is
strictly a measure of frequency, it does not account
for the highly variable functional limitations that may
result from bleeding. For example, a haemorrhage in
the knee may limit overall mobility, whereas bleeding
in an elbow may only limit the function of that single
limb. Further, even qualitatively similar joint bleeding
episodes vary in the degree to which they impact func-
tion. Moreover, an ABR of 0 in a patient with a
sedentary lifestyle is very different from the same ABR
in a patient with an active lifestyle. Thus, ABR cannot
account for inter-individual variability in bleeding pat-
terns and their functional sequelae, which are depen-
dent on factors such as disease severity, physical
activity and age [14,15]. Finally, evaluating ABR in
patients with pre-existing severe arthropathy is diffi-
cult, as the distinction between a new bleeding event
and a flare of arthritis pain cannot be readily assessed
[16].
With respect to clinical studies, the primary limita-
tion of the ABR is its lesser discriminatory capacity in
the era of prophylaxis. This limitation stems from the
fact that improvements in ABR are comparable across
clinical studies evaluating prophylaxis, with all studies
showing low mean/median frequencies of bleeding
[2,14,17–19]. Thus, using ABR as the sole endpoint to
discriminate among prophylactic approaches would
require an impractically large patient enrolment to
provide statistically meaningful power to discriminate
efficacy.
Joint status
Physical examination. Two current standards used for
research studies include the World Federation of
Hemophilia (WFH) Physical Examination Score (aka
Gilbert score) and the Haemophilia Joint Health Score
(HJHS) [11,14]. These tools assess joint status, incor-
porating range of motion, pain, deformity and swel-
ling, in the joints most commonly affected by bleeding
in haemophilia: the knees, ankles and elbows. The
HJHS is more commonly used, but requires extensive
training; it is best administered by physiotherapists
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experienced in haemophilia care. The HJHS provides
a total score, a joint-specific score and a global gait
score. It is available in four languages, can be used for
monitoring joint change over time in patients on pro-
phylaxis, and has been widely tested in children
[20,21]. It has also demonstrated good correlation
with the WFH score, haemarthroses and radiographic
damage [11]. However, neither the HJHS nor the
WFH score correlate well with bleeding rates, and nei-
ther instrument is sensitive enough to discriminate
change in patients at the extremes of the arthropathy
spectrum (i.e. with late-stage or early-stage joint dam-
age) [19]. More importantly, neither instrument mea-
sures functional status in daily life (e.g. the ability to
play a sport or to do a particular job).
Imaging. Various radiographic modalities have been
explored as a means to monitor haemophilia and the
effects of treatment, including X-rays, magnetic reso-
nance imaging (MRI) and ultrasonography [14]. X-ray
imaging has been used for many decades, with results
typically classified using the Arnold–Hilgartner system
[22] (progressive scale) or the Pettersson score [23]
(additive scale). Because X-ray detects changes in bone
structure, it is a widely accessible modality for mea-
suring change in advanced stages of arthropathy, but
it is insensitive to early changes in cartilage and soft
tissue [14].
In contrast, MRI is much more sensitive to changes
in cartilage and soft tissue compared with X-ray.
There are several MRI scales in current use, including
the Denver MRI score and the European MRI score.
This makes it difficult to compare data across treat-
ment centres, although a compatible scoring system
has been developed by the International Prophylaxis
Study Group [24]. Other drawbacks of MRI are its
high cost and the need for sedation when evaluating
children. Finally, MRI will not necessarily detect clini-
cally meaningful differences in joint outcomes in
adults [14], as in the SPINART study, where after
3 years, the prophylaxis group did not differ signifi-
cantly from the on-demand group on MRI despite a
significant reduction in ABR [25].
Ultrasonography is also sensitive to changes in carti-
lage and soft tissues and has the advantages of being
inexpensive, well accepted by patients and capable of
identifying and monitoring bleeding events in real time
[14,26]. In the recently reported Haemophilia Early
Arthropathy Detection with UltraSound (HEAD-US)
study, high-resolution ultrasonography detected a
higher percentage of abnormalities than the physical
evaluation and was concordant with the HJHS score
in 73% of joints [26]. Differences among operators
and instrument resolutions, however, can hinder com-
parability across treatment centres and/or across stud-
ies. While clearly promising as an outcome measure,
the use of ultrasound imaging techniques requires
further assessment to standardize operator training,
scoring systems and data interpretation [11,14].
Patient-reported outcome measures
Given the proven efficacy of prophylactic therapy for
reducing haemophilia-related morbidity, treatment
goals have shifted towards improving daily function-
ing and QoL, which are primarily assessed using
PROs [27,28].
Quality of life
Health-related QoL (HRQoL) tools evaluate the vari-
ous dimensions in the International Classification of
Functioning, Disability and Health (ICF) model of
health [29]. The overall health state in patients with
chronic medical conditions may be conceived of as a
complex interaction between specific impairments in
body structure and function, treatment effects on dis-
ease and symptoms, and occupation and lifestyle
(Fig. 1). Clinical studies in haemophilia have used
both generic and disease-specific instruments.
Generic HRQoL instruments such as the Medical
Outcomes Study Short-form 36 (SF36) and, more
recently, the EuroQoL (EQ-5D) have been used in
studies enrolling adult patients. These instruments are
designed to provide a comprehensive measure of vari-
ous aspects of daily life in functional, emotional and
social subscales, and have quantitative scoring systems
[6]. However, it should be noted that there is potential
for such measures to be influenced by social or eco-
nomic factors unrelated to the specifics of disease
management or by patient acceptance of compromised
function. In addition, for the sake of improved accu-
racy of recall, many such questionnaires restrict the
period of inquiry to the past 4 weeks; this creates
short-term perspectives that do not capture fluctuation
over longer time intervals, limiting applicability to
longitudinal assessments.
A number of haemophilia-specific HRQoL question-
naires have also been developed and used successfully
in clinical studies, including the HaemoQoL-A [30,31]
and HaemoQoL [32,33], Canadian Haemophilia Out-
comes-Kids Life Assessment (CHO-KLAT) and
Hemofilia-QoL. These instruments are used to evalu-
ate a patient’s current life experience across physical,
psychological and social domains. The HaemoQoL-A
(a self-report questionnaire for adults) and the Hae-
moQoL (a self-report questionnaire for children) have
both demonstrated good internal consistency, but only
the adult version meets the US Food and Drug Admin-
istration (FDA) criterion of using direct input from
patients to generate item content [3,34]. The
CHO-KLAT [35] is validated for use in five different
languages and cultures [36], but also does not meet
the FDA criterion for direct patient input during item
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development [37]. Inconsistencies have been observed
in the use of some response options [3,32] and, as
commonly observed in a paediatric population, par-
ent-proxy results were more reproducible than the
children’s results [36]. In addition, there is also the
Hemofilia-QoL, a 36-item questionnaire that has
demonstrated acceptable reliability and adequate con-
vergent validity with the SF-36 Health Survey [31].
However, similar to CHO-KLAT and HaemQoL, it
does not meet the FDA criterion of using direct input
from patients to generate item content [3] and its use
is limited to Spanish-speaking populations [31,38].
Of greater relevance to our concerns here, the com-
mon limitations of all haemophilia-specific QoL out-
come measures are that they were designed for use in
clinical research and may be time-consuming; conse-
quently, they have not been adopted in clinical prac-
tice. In addition, these instruments tend to be
comprehensive in their scope; consequently, not every
query may be of value to an individual patient [39].
Given that scoring systems are based on whole
domains or instruments, with raw scores normalized
to a predefined scale, the resultant integrated score
may mask the effect of treatment on a specific end-
point for an individual or subset of patients. For
example, knee and/or ankle arthropathy can limit
mobility but may not affect performance of a desk
job; in contrast, elbow arthropathy may not limit
mobility but would be more likely to have a deleteri-
ous impact on many job-related and domestic tasks.
Further, although either form of arthropathy may
result in low scores on a physical health domain, a
patient who is coping well might still score highly on
mental health. It is also possible for a similar masking
effect to occur in the same patient evaluated at differ-
ent timepoints because the parameters of change, even
within specific domains, vary across time. However,
the authors are not aware of any empirical evidence
of masking effects using haemophilia-specific QoL
instruments.
A recent review of the limitations of outcome mea-
sures in haemophilia observed that, to satisfy the
requirements for autonomy, a QoL measure should
allow patients to pick those domains and items of life
that have the most meaning to them; moreover, to be
truly individualized, a QoL tool should allow patients
to define their own values, expectations, hopes and
realizations for each of these items [12]. No current
haemophilia QoL measure satisfies these criteria.
Functional assessment
Currently, two haemophilia-specific tools evaluate per-
formance in everyday activities. These are the Hae-
mophilia Activities List (HAL) and its paediatric
version (PedHAL), and the Functional Independence
Score in Haemophilia (FISH) [12–14]. The HAL cov-
ers a wider range of activities, including work, hob-
bies, social and sporting activities, takes
approximately 10 minutes to complete and is avail-
able in numerous languages [40]. However, it is not
applicable to certain cultures and has demonstrated
limited ability to detect clinical changes over time.
Further, the test–retest reliability of the HAL has not
been assessed, nor has the PedHAL been validated in
children [13,14].
The FISH allows for an in-clinic evaluation of activ-
ities of daily living [13,41] and is particularly useful
for physically impaired patients. It can evaluate
changes in functional independence and takes into
account daily-life activities that could be affected by
haemophilia. It is relatively easy to administer, does
not require special training and has demonstrated high
internal consistency and excellent reliability [11–14].
In addition, FISH has demonstrated good correlation
with general functional ability tests (Health Assess-
ment Questionnaire [HAQ], Western Ontario McMas-
ter [WOMAC], Canadian Occupational Performance
Measure [COPM]) [42–44], and is currently being
modified for use in children. Despite these strengths,
the instrument has several limitations. It is least useful
in patients with mild arthropathy (i.e. it is not sensi-
tive to minor functional impairment), and it does not
consider impact on vocational aspects such as educa-
tion or employment [13,14].
Overall, the comprehensive nature of PROs dis-
cussed thus far render them prone to the loss of sensi-
tivity to change in specific domains relevant to each
patient, which occurs because patients must respond
to every item of a fixed instrument, including those
that are of little or no importance to them. Thus, clin-












Fig. 1. Interactions between disease parameters,
treatment effects and patient lifestyle determine
overall health state.
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treatment outcomes of particular relevance to the indi-
vidual patient. Taken together, it is clear that the fixed
nature of most PRO instruments inherently limits their
discriminative capacity, suggesting that a less compre-
hensive but more individually defined instrument may
be warranted to better measure treatment effects. The
challenge would be to execute this process in a sys-
tematic and valid manner to allow for the consistent
evaluation of diverse treatment effects [39].
Development of new outcome measures
The key limitation of the outcome measures discussed
thus far, whether clinical or patient-reported, is lack
of personalization, resulting in the inability to measure
what matters most to an individual patient. In addi-
tion, many of these measures have limited applicabil-
ity to routine clinical care, primarily because of the
large investment of time required, and are therefore
used almost exclusively in research studies. Here, we
present a brief introduction to outcome measures in
development that are designed to accommodate cus-
tomization/personalization of outcomes, thereby pro-
viding adequate discriminatory capacity to detect
longitudinal changes in the short and long term, in
clinical care and in research.
Patient-Reported Outcomes Measurement
Information System (PROMIS)
The PROMIS program was launched in 2004 by the
US National Institutes of Health to provide clinicians
and researchers access to ‘efficient, precise, valid and
responsive adult- and child-reported measures’ in the
physical, mental and social domains that could be
applied across a broad range of chronic medical con-
ditions [45]. The PROMIS program uses modern mea-
surement theory to develop and improve PRO
measures in part through utilizing item response the-
ory, a psychometric method used to produce proba-
bilistic scores (calibrations) associated with answers to
questions (items) [39].These calibrations can be used
by computerized adaptive testing (CAT) to select the
most informative follow-up question to an initial
question from a predetermined bank of questions.
Alternatively, customized short-form questionnaires
could be developed from these banks.
In essence, PROMIS instruments represent an incre-
mental improvement in psychometric assessment of
QoL, achieved through more sophisticated item devel-
opment and selection. The domains and their respec-
tive comprehensive bank of items are available for
both adult and paediatric populations and in many
cases have been translated into several international
languages. Questionnaires may be customized by user-
based selection of items. From a structural perspective,
there is a well-described trade-off between comprehen-
siveness and the ability to discriminate change. The
more items included, the more comprehensive the
measure, but the less likely it is to discriminate change
[39]. Conversely, although including fewer items
reduces this potential masking effect, it also increases
the likelihood that items of importance to some
patients will be excluded. To some degree, the CAT
approach may ameliorate this inherent problem
because the algorithm can select the most appropriate
item from a predefined bank based on the individual’s
response to a prior question [45]. Disease states in
which PROMIS measures have been used include:
sickle cell disease [46] asthma [47] and rheumatoid
arthritis [48].
The PROMIS website also provides a secure plat-
form and automated scoring system that can be
deployed in the clinical trial or everyday practice set-
tings. While further development would need to incor-
porate some items specific to haemophilia
populations, the overall concept and design is a step
in the direction of providing a more robust, and to
some extent, customized approach to measuring
PROs. Nonetheless, there are inherent limitations on
how personalized PROMIS instruments can be used
because they are not based on the preferences or
values of individual patients.
Goal attainment scaling
An established approach for identifying and quantitat-
ing change in individuals and groups affected by
chronic conditions is the strategy of goal attainment
scaling (GAS). The concept was first developed in the
1960s by Kiresuk and Sherman for patients with men-
tal illness [49]. This alternative approach does not use
a questionnaire-type instrument and does not measure
patient experience or functioning across various
domains. Instead, GAS assesses the extent to which
treatment, after a specified period of time, results in
the attainment of a set of personally important goals,
selected by the patient at the outset, that are related
to clinical or functional impacts of a particular condi-
tion. GAS can be thought of as a standardized
approach to patient-centred, solution-oriented care,
which is often practised informally, without clear
measurement or quantification [50–52]. GAS has been
applied successfully in both clinical practice and
research in patients with a broad range of other
chronic conditions, including dementia [51], diabetes
[7], acquired brain injury [53] and various types of
physical disability [50]. The critical feature of GAS
that allows for the detection of small but clinically
meaningful change is the fact that it is personalized
for every patient, comprising only outcomes of impor-
tance to the individual patient.
© 2016 The Authors. Haemophilia Published by John Wiley & Sons Ltd. Haemophilia (2016), 22, 825--832
PERSONALIZED OUTCOME MEASURES IN HAEMOPHILIA 829
A comprehensive discussion of GAS methodology is
beyond the scope of this paper. In brief, GAS requires
patients and health care providers to work together to
identify treatment goals that have the greatest rele-
vance. Predefined outcomes are used to define a scale
that provides a quantitative measure of the extent of
achievement of the individual’s goal(s). Goal attain-
ment is scored on a five-point scale (Table 1). The
baseline state is set at 1 and the specified goal at 0,
with progressively better outcomes scored as +1 and
+2 and an outcome worse than baseline as 2. For
example, a relevant goal for a juvenile or adult patient
with severe haemophilia A may be ‘not missing more
than 20 days of school or work in a year,’ and 5-day
increments or decrements thereof may represent better
or worse outcome levels. Using a standard formula,
goal attainment scores may be generated for individu-
als or groups, and these scores compared with one
another [54].
We are currently working to adapt GAS for use in
haemophilia [55]. In some settings, such as geriatric
rehabilitation [56] and dementia [51], menus of likely
goal areas and descriptions of a range of attainment
levels for each goal area have been developed to aid
patients in goal setting. The authors and an interdisci-
plinary group of colleagues are involved in a system-
atic approach to accomplish a similar objective in
haemophilia (i.e. to provide multiple examples of goal
areas and descriptions of attainment levels) (Table 2).
First, cross-disciplinary workshops were held to con-
struct a menu of goal areas (Fig. 2) and associated
levels of goal attainment. This initial work was fol-
lowed by systematic gathering of patient and family
input to refine the language, validate the goals and
identify any gaps. Input from patients and families
confirmed that this approach may be particularly rele-
vant in haemophilia, where patients represent a wide
spectrum of variation in age, disease severity, disabil-
ity and psychosocial characteristics [54]. The instru-
ment developed by this process, called Goal
Attainment Scaling for Hemophilia (GOAL-Hem), is
currently being evaluated in a multi-centre, North
America-based feasibility study, using an online plat-
form to facilitate training, implementation and data
management (Fig. 2). The feasibility study will help
address the issues of what constitutes clinically mean-
ingful change and whether it can be reliably measured.
The study will also evaluate the versatility of
Table 1. Goal attainment scaling (GAS) scale.
Score value Goal outcome
+2 Much better than expected
+1 Somewhat better than expected
0 Expected outcome (goal)
1 Somewhat worse than expected (baseline)
2 Much worse than expected
Table 2. Selected goal areas in haemophilia.
General category Goal area
Managing haemophilia Being able to administer factor
Weight, exercise and nutrition
Haemophilia complications Joint problems
Pain








Partnered with GAS experts to build the tool
Obtained extensive patient input to inform the development of the item menu
Evaluated the feasibility of using the GAS outcome measure in the clinic
Validates the GAS outcome measure in a clinical study
Engaged haemophilia experts representing various disciplines
and with extensive clinical and/or research experience
Defined goal areas and behavioural descriptors specific to haemophilia patients
(eg, activity/exercise-, joint health-, school/work-, disease management-related)
Fig. 2. [Concept Illustration] Flow Chart of
development of the Goal Attainment Scaling for
Haemophilia instruments.
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GOAL-Hem [52,55]; i.e. use across all age groups
with all levels of disease severity, and in different
socioeconomic circumstances. Finally, by facilitating
collaboration between patients and their healthcare
providers, GOAL-Hem may encourage patients to
engage more actively in their treatment.
The fundamental advantage of GOAL-Hem is that
it allows for individualization of the outcome measure
itself. For example, a common goal for paediatric
patients (approximate ages 10–15) is to become com-
petent and responsible for self-infusion of factor con-
centrate. This goal area can be selected, current
baseline functioning assessed and quantifiable degrees
of improvement described to define potential out-
comes. In this way, the GAS-based PRO tool provides
a truly personalized outcome measure.
The main limitation of GAS as an outcome measure
is the degree to which it is operator dependent. In
addition, there are operational challenges, including
the need for initial staff training and the time and
other resources required for implementation and ongo-
ing use of the instrument. These issues will be a major
focus of the feasibility study.
Conclusions
In the era of prophylaxis, outcome measures that can
discriminate treatment effects important to individual
patients are needed in both clinical care and research.
While recognizing the strengths of the various outcome
measures currently used in haemophilia research, none
of these measures are personalized or have sufficient
discriminatory capacity to detect change in clinically
meaningful parameters that are important to patients
with haemophilia in the developed world today. In
addition, the existing PRO measures have all been
designed for use in clinical research and have limited
applicability to real-world treatment.
Efforts to develop more powerful tools to measure
PROs in haemophilia are underway. We have pre-
sented two of these here. The first, PROMIS, opti-
mizes the value of the questionnaire-based approach
common to most PROs. The other, GAS, represents a
fundamentally different approach that is based on
patient-selected goals and measures the extent to
which these goals are attained. We believe that this
approach most directly addresses the need for person-
alization of outcome measurement in haemophilia.
Adoption of this or a similarly qualified patient-centric
outcome measure will provide clinicians and research-
ers with an important innovation that addresses the
contemporary challenge of measuring incremental but
clinically meaningful improvement in haemophilia
patients.
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